Survival outcomes (mPFS 8.2 months; 12-month OS 80.8%) compare favorably with typical first-line chemo-immunotherapy benchmarks near 5 months mPFS in ES-SCLC. Mechanistically, EGFR/HER3 targeting plus ...
Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic medicines in the United States, today announced the launch of Milnacipran HCl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results